Trials / Completed
CompletedNCT06345885
Immunogenicity and Safety of One Dose of HPV Vaccine
Immunogenicity and Safety of One Dose of Cecolin and One Dose of Gardasil
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Xiamen Innovax Biotech Co., Ltd · Industry
- Sex
- Female
- Age
- 9 Years – 14 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the immunogenicity and safety of one dose of Cecolin and one dose of Gardasil
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HPV vaccine | Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months |
Timeline
- Start date
- 2023-02-23
- Primary completion
- 2024-01-17
- Completion
- 2024-01-17
- First posted
- 2024-04-03
- Last updated
- 2024-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06345885. Inclusion in this directory is not an endorsement.